Business
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its

About this update from Insulet Corporation
ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025 , before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time) . The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com , “Events and Presentations,” and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2109 for international callers, passcode is 5904836. About Insulet Corporation : Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts , is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: Insulet.com or omnipod.com . ©2025 Insulet Corporation . Omnipod is a registered trademark of Insulet Corporation . All rights reserved. View source version on businesswire.com : https://www.businesswire.com/news/home/20250708347745/en/ Investor Relations: June Lazaroff Senior Director, Investor Relations (978) 600-7718 [email protected] Media: Angela Geryak Wiczek Senior Director, Corporate Communications (978) 932-0611 [email protected] Source: Insulet Corporation
View stock analysis, news, and events for Insulet Corporation